A study published on Pharmacoeconomics on October 12 reveals that pulmonary arterial hypertension continues to be associated with a very high economic burden and healthcare resource utilization across all payer types within the US healthcare system. The study included 11,670 patients enrolled in Medicare Fee-for-Service, 1,021 patients enrolled in Medicare Advantage, 274 patients enrolled in Medicaid, and 1,174 patients with commercial insurance in the US. The annual national financial burden to payers was estimated to be 3.1 billion US dollars. The per patient per month (PPPM) costs for payers ranged from $6,500 to $14,742, while out-of-pocket costs ranged from $341 to $907 per patient per month.
Fortunately, in some parts of the world, treatments for pulmonary arterial hypertension do not impose a significant economic burden on patients, allowing for more equitable access to necessary care and improving the quality of life for those affected by this condition.
Photo credit Carolina Grabowska on Pexels
Read the full article at this link on Springer Nature Link
Citation
Watzker A, Alsumali A, Ferro C, Dieguez G, Park C, Lautsch D, El-Kersh K. Economic Burden Associated with Pulmonary Arterial Hypertension in the United States. Pharmacoeconomics. 2024 Oct 12. doi: 10.1007/s40273-024-01427-2. Epub ahead of print. PMID: 39395085.
